08:36 AM EDT, 08/26/2024 (MT Newswires) -- MIRA Pharmaceuticals ( MIRA ) shares surged nearly 46% in Monday's premarket activity after reporting that a pre-clinical study in rats showed that its ketamine analog, Ketamir-2, resulted in a 100% normalization of pain thresholds at the highest dose.

"This effect stands in stark contrast to traditional ketamine, which proved ineffective orally under the same experimental conditions," the company said in a statement.

MIRA said that because of the positive results, it will conduct more studies to evaluate Ketamir-2's efficacy in treating cancer-induced depression and neuropathic pain.

"The development of Ketamir-2 as an oral treatment for neuropathic pain is a significant milestone not only for MIRA but for the entire field of neuropsychiatric and neurologic disorder therapies," MIRA Chairman and Chief Executive Erez Aminov said.

Price: 2.6999, Change: +0.85, Percent Change: +45.94